Condition: Ann Arbor Stage II Follicular Lymphoma · Grade 1 Follicular Lymphoma · Ann Arbor Stage III Follicular Lymphoma · Sponsor: Chinese PLA General Hospital
This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .
This description comes directly from the study's public registry record.
YANG LIU, MD · 010-66937463 · liuyang301blood@163.com
Always discuss trial participation with your own doctor first.
| Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06471738